Biden vs. Pharma: ‘You Come For The King…’
Executive Summary
The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.
You may also be interested in...
End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.
Did The US FDA Mix Politics And Science With Its Cancer Guidance Announcement?
Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.
Democratic Drug Pricing Push: Starting And Ending With Insulin?
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.